Novo Nordisk blueprints its obesity R&D push in Seattle

Novo Nordisk's Seattle R&D center

Novo Nordisk ($NVO) has made it official: The Danish drugmaker is making a full-fledged go at obesity R&D, looking to build a Seattle hub and hire some investigators as it expands its research palate. The obesity branch will initially employ about 10 people, Novo said, growing to around 60 workers by 2016. Around the globe, the company expects to devote about 300 researchers to the obesity effort. Report

Suggested Articles

The future may be uncertain for AZ’s Imfinzi in first-line lung cancer, but its targeted med Tagrisso now boasts a green light in that setting.

Ultragenyx is back with another FDA nod, this time for Crysvita to treat X-linked hypophosphatemia in patients one year and older.

Roche got a two pieces of good Hemlibra news early this week—and what's good for Hemlibra must be good for Roche.